{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:40:00Z","timestamp":1791866400656,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jdiacomp.2025.109181","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:22:01Z","timestamp":1760001721000},"page":"109181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-7161","authenticated-orcid":false,"given":"Nikolaos","family":"Angelopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarantis","family":"Livadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rizoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Boniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodis","family":"Paparodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploutarchos","family":"Tzoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voula","family":"Mentzelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Florakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Fousteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti","family":"Korakovouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Zianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zadalla","family":"Mouslech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109181_bb0005","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.clinthera.2023.06.008","article-title":"Effect of the dual glucose-dependent insulinotropic peptide\/glucagon-like peptide 1 receptor agonist tirzepatide on lipid profile and waist circumference: a systematic review and meta-analysis","volume":"45","author":"Yu","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/obesities5020026","article-title":"Efficacy and safety of tirzepatide for weight management in non-diabetic obese individuals: a narrative review","volume":"5","author":"Sallam","year":"2025","journal-title":"Obesities"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/DMSO.S392684","article-title":"Novel anti-obesity therapies and their different effects and safety profiles: a critical overview","volume":"16","author":"Caklili","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01025-w","article-title":"Metabolic health and adiposity transitions and risks of type 2 diabetes and cardiovascular diseases: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11154-023-09825-1","article-title":"Beyond glycemia: comparing tirzepatide to GLP-1 analogues","volume":"24","author":"Andraos","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14656566.2024.2436595","article-title":"Tirzepatide for overweight and obesity management","volume":"26","author":"Hamza","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0070","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0075","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/nu17071216","volume":"17","author":"Schiavo","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/DMSO.S443396","article-title":"The effect of tirzepatide on weight, lipid metabolism and blood pressure in overweight\/obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"17","author":"Lv","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0090","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.cmet.2024.06.012","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0095","first-page":"1029","article-title":"Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice","volume":"119","author":"Han","year":"2009","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-024-02416-2","article-title":"Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics","volume":"24","author":"Liang","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MOL.0000000000000824","article-title":"Small dense low-density lipoprotein particles: clinically relevant?","volume":"33","author":"Krauss","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108800","article-title":"Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: a step closer to drug-induced diabetes remission?","volume":"38","author":"Popovic","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/1570161114666160722112738","article-title":"Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?","volume":"14","author":"Katsiki","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/00033197211014676","article-title":"Perivascular adipose tissue: pathophysiological links with inflammation, atherosclerosis, and thrombosis","volume":"73","author":"Katsiki","year":"2021","journal-title":"Angiology"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0145","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0155","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0165","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155211","article-title":"Effects of statins on specialized pro-resolving mediators: an additional pathway leading to resolution of inflammation","volume":"132","author":"Radbakhsh","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0175","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2025.109181_bb0180","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14740338.2023.2247984","article-title":"Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!","volume":"22","author":"Patoulias","year":"2023","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272500234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272500234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:19:34Z","timestamp":1763788774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687272500234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S105687272500234X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109181","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109181"}}